The ADDRESS-LC data are hypothesis-generating but lack a primary endpoint hit in the overall population, making a Phase 3 design uncertain. Watch for biomarker data (pending future presentation) and any FDA feedback on the subgroup findings. The stock's history of extreme volatility around news events suggests outsized moves are possible, but the clinical signal is modest.
Price Chart
Executive Summary
BioVie presented Phase 2 ADDRESS-LC data for bezisterim in Long COVID at ANA 2026. The trial did not achieve statistical significance on any endpoint in the overall ITT population; positive results were limited to pre-specified subgroup analyses (patients with high baseline fatigue, PEM, or cognitive impairment).
Key Financial Metrics
Key Facts
- Phase 2 ADDRESS-LC trial (n=203) did not achieve statistical significance on any endpoint in the overall ITT population.
- Statistically significant improvements were observed in pre-specified subgroups: patients with high baseline fatigue (PROMIS Fatigue T-score ≥65), high PEM (DSQ-PEM ≥67.5), or objective cognitive impairment (Cogstate z-score ≤0.130).
- Bezisterim showed a safety profile comparable to placebo (41.6% vs 55.9% TEAEs; no serious TEAEs in bezisterim group).
- The study is fully funded by a $13.13 million U.S. Department of War award.
- No FDA-approved treatments currently exist for Long COVID.
- Subgroup analyses are hypothesis-generating and may not be replicated in future trials.
Financial Impact
No revenue or financial data reported; Phase 2 results are exploratory and do not directly impact near-term financials. The DoW award of $13.13M covers the study cost.
Risk Factors
- No primary endpoint met in the overall ITT population; subgroup results may not replicate in a confirmatory Phase 3 trial.
- Biomarker data are still pending and may not correlate with clinical benefit.
- BioVie is a clinical-stage company with no approved products and will need additional capital to fund further development.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383392 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $1.37 | awaiting T+20 | — | $1.44 (+5.11%) |
Sep 15, 2026 6w ago | Press Release | $1.75 $1.20 | ▼ −31.43% | ▼ −34.41% | $1.44 (−17.71%) |
Aug 14, 2026 10w ago | S-1/A | $1.17 $1.75 | ▼ −49.57% | ▼ −51.55% | $1.44 (−23.08%) |
Aug 6, 2026 11w ago | S-1/A | $1.35 $2.03 | ▼ −50.37% | ▼ −49.77% | $1.44 (−6.67%) |
Aug 6, 2026 11w ago | 8-K | $1.35 $2.03 | ▲ +50.37% | ▲ +49.77% | $1.44 (+6.67%) |
Jul 31, 2026 12w ago | S-1/A | $1.62 $2.28 | ▼ −40.74% | ▼ −39.50% | $1.44 (+11.11%) |
Jun 30, 2026 17w ago | EFFECT | $1.94 $1.37 | ▲ +29.38% | ▲ +28.35% | $1.44 (+25.77%) |
Apr 27, 2026 26w ago | Press Release | $1.59 $1.44 | ▼ −9.43% | ▼ −14.39% | $1.44 (−9.43%) |
Apr 14, 2026 28w ago | Press Release | $1.46 $1.35 | ▼ −7.53% | ▼ −13.83% | $1.44 (−1.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers